File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma

TitleProspective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma
Authors
KeywordsActurial survival
Adjuvant chemotherapy
Distant metastatis
Head and neck cancer
Issue Date2001
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejso
Citation
European Journal Of Surgical Oncology, 2001, v. 27 n. 8, p. 750-753 How to Cite?
AbstractAims: A prospective randomized study was conducted to evaluate the benefit of adjuvant levamisole/UFT (futraful and uracil) chemotherapy in head and neck squamous cell carcinoma. Methods: Sixty-five patients with stage III and IV squamous cell carcinomas of oral cavity, oropharynx, hypopharynx and larynx with no distant metastasis were randomized for the chemotherapy study. Thirty-one patients were randomized for chemotherapy and two of them were subsequently excluded. In this study, a total of 29 patients on levamisole/UFT therapy and 34 patients on the control group were analysed. The main outcome was measured by the 5-year disease-free actuarial survival rate. Results: The rates of distant metastasis were 10% for chemotherapy group and 32% for control group (P=0.06). The 5-year disease-free actuarial survival rates for patients with and without adjuvant chemotherapy were 57% and 39% respectively (P=0.207). Conclusions: A trend of better distant control in head and neck cancer patients with post-operative adjuvant oral chemotherapy was observed. The side effects were minimal. However, there was no statistically significant improvement in the overall long-term survival. It may be of value to conduct a large-scale multi-centre prospective randomized study to verify the efficacy of levamisole and UFT as post-operative adjuvant chemotherapy for the control of distant metastasis in high-risk population. © 2001 Harcourt Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/84451
ISSN
2015 Impact Factor: 2.94
2015 SCImago Journal Rankings: 1.327
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, Pen_HK
dc.contributor.authorYuen, APWen_HK
dc.contributor.authorHo, CMen_HK
dc.contributor.authorHo, WKen_HK
dc.contributor.authorWei, WIen_HK
dc.date.accessioned2010-09-06T08:53:07Z-
dc.date.available2010-09-06T08:53:07Z-
dc.date.issued2001en_HK
dc.identifier.citationEuropean Journal Of Surgical Oncology, 2001, v. 27 n. 8, p. 750-753en_HK
dc.identifier.issn0748-7983en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84451-
dc.description.abstractAims: A prospective randomized study was conducted to evaluate the benefit of adjuvant levamisole/UFT (futraful and uracil) chemotherapy in head and neck squamous cell carcinoma. Methods: Sixty-five patients with stage III and IV squamous cell carcinomas of oral cavity, oropharynx, hypopharynx and larynx with no distant metastasis were randomized for the chemotherapy study. Thirty-one patients were randomized for chemotherapy and two of them were subsequently excluded. In this study, a total of 29 patients on levamisole/UFT therapy and 34 patients on the control group were analysed. The main outcome was measured by the 5-year disease-free actuarial survival rate. Results: The rates of distant metastasis were 10% for chemotherapy group and 32% for control group (P=0.06). The 5-year disease-free actuarial survival rates for patients with and without adjuvant chemotherapy were 57% and 39% respectively (P=0.207). Conclusions: A trend of better distant control in head and neck cancer patients with post-operative adjuvant oral chemotherapy was observed. The side effects were minimal. However, there was no statistically significant improvement in the overall long-term survival. It may be of value to conduct a large-scale multi-centre prospective randomized study to verify the efficacy of levamisole and UFT as post-operative adjuvant chemotherapy for the control of distant metastasis in high-risk population. © 2001 Harcourt Publishers Ltd.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejsoen_HK
dc.relation.ispartofEuropean Journal of Surgical Oncologyen_HK
dc.subjectActurial survivalen_HK
dc.subjectAdjuvant chemotherapyen_HK
dc.subjectDistant metastatisen_HK
dc.subjectHead and neck canceren_HK
dc.titleProspective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0748-7983&volume=27&spage=750&epage=753&date=2002&atitle=Prospective+randomized+study+of+post-operative+chemotherapy+with+levamisole+and+UFT+for+head+and+neck+carcinomaen_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/ejso.2001.1171en_HK
dc.identifier.pmid11735172-
dc.identifier.scopuseid_2-s2.0-0035176774en_HK
dc.identifier.hkuros116900en_HK
dc.identifier.hkuros65984-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035176774&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue8en_HK
dc.identifier.spage750en_HK
dc.identifier.epage753en_HK
dc.identifier.isiWOS:000172443300010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, P=7202366058en_HK
dc.identifier.scopusauthoridYuen, APW=7006290111en_HK
dc.identifier.scopusauthoridHo, CM=7404652540en_HK
dc.identifier.scopusauthoridHo, WK=7402968844en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats